Bristol-Myers Squibb and SystImmune said that their drug Iza-bren achieved statistically significant improvements in survival across three Phase 3 trials [1], [2].
These results are critical because they demonstrate the therapeutic potential of the drug across multiple tumor types, potentially paving the way for regulatory approval and wider commercial availability for high-risk cancer patients.
The studies, which were conducted in Chinese patient populations, focused on overall survival and progression-free survival [2], [3]. The data indicates that Iza-bren, also known as izalontamab-brengitecan, provided clinically meaningful benefits in patients battling triple-negative breast cancer and esophageal squamous-cell carcinoma [2].
In the specific Phase 3 trial for advanced breast cancer, the drug met its primary endpoints for both progression-free survival and overall survival [3]. This success is part of a broader effort by the two companies to validate the drug's efficacy in diverse oncology settings.
The announcement of these findings occurred on June 2, 2024 [1]. SystImmune, a subsidiary of Sichuan Biokin Pharmaceutical, collaborated with Bristol-Myers Squibb to develop and test the bispecific antibody-drug conjugate.
While some reports focused exclusively on the breast cancer data, the broader analysis confirmed that benefits were observed across three separate Phase 3 trials in China [2]. The companies said they intend to use these results to support further regulatory advancements for the treatment.
“Iza-bren achieved statistically significant improvements in survival across three Phase 3 trials.”
The success of Iza-bren in Phase 3 trials suggests a potential shift in treatment options for aggressive cancers like triple-negative breast cancer, which often have limited therapeutic responses. By demonstrating efficacy in both breast and esophageal cancers, the partnership between Bristol-Myers Squibb and SystImmune is positioning the drug as a versatile tool in oncology, though the current data is limited to Chinese patient populations.
